The PARP7 inhibitor RBN2397 is currently tested in phase-1 clinical trials, both in breast and lung cancer cells, enhancing the IFN-I signalling pathways negatively regulated by PARP7, and in prostate cancer cells, where PARP7 regulates the stability of AR, leading to an inhibition of prostate cancer cells growth in culture (Ref. The gene discussed is TIPARP; the disease is lung carcinoma.